CRDF - CIK 0001213037
Cardiff Oncology, Inc. trades as CRDF. In its fiscal 2025 annual report the company posted revenue of $593.00K, down 13.2% from the prior year and net income of -$45.85K. This page tracks Cardiff Oncology, Inc. through 1,000 SEC filings, with financial statements and metrics updated as new reports are filed.
Over the last 9 fiscal years Cardiff Oncology, Inc.'s revenue grew from $381.07K to $593.00K, a compound annual growth rate of 5.0%. Net profit margin expanded from -10287.7% to -7.7% over the same period - every figure below comes from the company's audited annual filings.
| Filing | Type | Filed |
|---|---|---|
| Major company event | 8-K | 2026-05-19 |
| Major company event | 8-K | 2026-05-14 |
| Quarterly report | 10-Q | 2026-05-14 |
| Insider trade | 4 | 2026-04-28 |
| New insider ownership | 3 | 2026-04-28 |
| Proxy materials | DEFA14A | 2026-04-23 |
| Proxy statement | DEF 14A | 2026-04-23 |
| Annual report to shareholders | ARS | 2026-04-23 |
The largest companies sharing Cardiff Oncology, Inc.'s SEC industry classification (biological products, (no diagnostic substances)).
Cardiff Oncology, Inc. reported revenue of $593.00K for fiscal year 2025, a decrease of 13.2% year over year.
In its latest fiscal year Cardiff Oncology, Inc. reported a net loss of $45.85K.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
Dig into the full income statement, balance sheet, and cash flow statement with annual and quarterly views.